A first-in-human Claudin 18.2–targeted antibody-drug conjugate; a monoclonal antibody binds CLDN18.2 on tumor cells, is internalized, and releases a cytotoxic topoisomerase I inhibitor payload causing Topo‑I inhibition, DNA damage, and tumor cell death; administered every 3 weeks.
Monoclonal antibody targets CLDN18.2 on tumor cells, is internalized, and releases a cytotoxic topoisomerase I inhibitor payload via linker cleavage, leading to Topo-I inhibition, DNA damage, and tumor cell death.
YES
DIRECT
ADC binds CLDN18.2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload after linker cleavage, causing DNA damage and apoptotic cell death.
A first-in-human Claudin 18.2–targeted antibody-drug conjugate; a monoclonal antibody binds CLDN18.2 on tumor cells, is internalized, and releases a cytotoxic topoisomerase I inhibitor payload causing Topo‑I inhibition, DNA damage, and tumor cell death; administered every 3 weeks.
Monoclonal antibody targets CLDN18.2 on tumor cells, is internalized, and releases a cytotoxic topoisomerase I inhibitor payload via linker cleavage, leading to Topo-I inhibition, DNA damage, and tumor cell death.
NO
INDIRECT
XNW27011 is an anti‑CLDN18.2 ADC. It binds CLDN18.2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor that causes DNA damage. Topoisomerase I is not the recognized surface target; cells are only killed if they express CLDN18.2, not merely Topo I.
Anti-CD73 monoclonal antibody–drug conjugate administered IV; blocks CD73-mediated adenosine production and delivers the cytotoxic payload SN38 to CD73-expressing cells, inducing DNA damage via topoisomerase I inhibition.
Anti-CD73 monoclonal antibody–drug conjugate that binds and inhibits CD73 (ecto-5′-nucleotidase), reducing extracellular adenosine and associated A2A/A2B receptor–mediated immunosuppression, while delivering the topoisomerase I–inhibiting payload SN38 to CD73-expressing cells to induce DNA damage and apoptosis.
YES
DIRECT
The anti-CD73 ADC binds CD73 on target cells, is internalized, and releases SN38 (a topoisomerase I inhibitor) that induces DNA damage and apoptosis in CD73-expressing cells.
Anti-CD73 monoclonal antibody–drug conjugate administered IV; blocks CD73-mediated adenosine production and delivers the cytotoxic payload SN38 to CD73-expressing cells, inducing DNA damage via topoisomerase I inhibition.
Anti-CD73 monoclonal antibody–drug conjugate that binds and inhibits CD73 (ecto-5′-nucleotidase), reducing extracellular adenosine and associated A2A/A2B receptor–mediated immunosuppression, while delivering the topoisomerase I–inhibiting payload SN38 to CD73-expressing cells to induce DNA damage and apoptosis.
NO
INDIRECT
HB0052 binds CD73, is internalized, and releases SN38; SN38 inhibits topoisomerase I to cause DNA damage and apoptosis. Killing is directed at CD73-expressing cells, not at cells defined by topoisomerase I expression.
Chimeric IgG1 anti-EGFR monoclonal antibody that binds EGFR (ErbB1), inhibits downstream signaling (MAPK/PI3K), and can mediate ADCC; administered at 75 mg in this study.
Chimeric IgG1 monoclonal antibody that binds the extracellular domain of EGFR (ErbB1), blocking ligand binding and receptor dimerization to inhibit downstream MAPK/PI3K signaling and tumor cell proliferation; can also mediate ADCC.
YES
DIRECT
Cetuximab binds EGFR on target cells and engages Fcγ receptors on NK cells/macrophages to trigger ADCC (and can activate complement), resulting in killing of EGFR+ cells; EGFR blockade is mainly cytostatic.